![]() |
![]() |
A cautionary not from the SKEPTICS. With corporate medicine profits are the measure of treatment. Arrhythmia is not an exception. There are extreme cases where intervention is life-prolonging, but in most cases the harm is greater than the benefit. More articles will be appearing on this topic shortly. 12 out of 17 families had arrhythmia as the cause of death. Recommendation that for families with sudden, early cardiac deaths, relatives should be tested. Circulation published by American Heart Association Published online before print 1&%3bauthor1=Wilde&%3bandorexacttitle=and&%3bandorexacttitleabs= and&%3bandorexactfulltext=and&%3bsearchid= 1131610821138_71&%3bstored_search=&%3bFIRSTINDEX=0&%3bsortspec= relevance&%3bfdate=6/1/2005&%3bsearch_url=http%253A%252F% 252Fwww.ahajournals.org%252Fcgi%252Fsearch Circulation.
2005;112:207-213.) |
![]() |
|
![]() |
![]() |
![]() |
Enter supporting content here Those who have a financial interest in the outcome manipulate the results, Major study finds that all 37 journal articles positive effects over stated; the average was 32%. Statins cause erectile dysfunction, cognitive imparement, and cancer. Lipitor (2011) lifetime sales $131
billion, tops all drugs. Plavix at
$60 billion is second.
STATINS CANCER Link 52% short term LA Times, Health section, Vytorin, the
combination drug (simvastatin (better known by its commercial name Zocor) and ezetimibe--known as Zetia) prescribed to lower
cholesterol, sustained another blow today, when the author of a major clinical trial announced that the medication had failed
to drive down hospitalization and death due to heart failure in patients with narrowing of the aortic valve. In the process,
researchers in Today's findings
suggested something more ominous: the incidence of cancer -- and of dying of cancer -- was significantly higher in the patients
taking Vytorin. Altogether, 67 patients on placebo developed cancer during the trial.
Among subjects on Vytorin, 102 developed cancers of various kinds.* This
is the second adverse press—the first being in March 08, when the ENHANCE trial found that Vytorin fared no better than
a placebo at reducing plaque buildup on the walls of patients' arteries.* * Comments by jk Simvastatin (Zocor) is off patent. Thus in a scramble for profits a combination drug (on patent) was introduced. Direct to consumer market cost $155 in 07—mainly TV ads. * The pressing issue is that since the development of Statins, the very first animal studies in the 60s it has been known that Statins increase the incidents of cancer. However, nearly all studies done thereafter have not included cancer. *
Several studies have failed to find a reduction in the build of plaque, even thought the statins including Zocor, reduce
EXTENDED RELEASE NIACIN IS A SAFER, AND A MORE EFFECTIVE WAY TO LOWER MI RISK! |